InDex's Lead TLR9 Agonist Shows Promise In Ulcerative Colitis
A Toll-like receptor-9 agonist under development by Sweden’s InDex Pharmaceuticals showed encouraging clinical responses in top-line results in patients with active ulcerative colitis not responding to other agents. Its novel mechanism of action and relatively benign side effect profile makes it a prime candidate to combine with biologic agents.
You may also be interested in...
Mologen’s CEO tells Scrip the German biotech will only pursue combination studies in future after its lead candidate lefitolimod failed as a monotherapy in a pivotal trial treating metastatic colorectal cancer patients.
2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more...
Almirall has returned ulcerative colitis therapy Kappaproct to its originator company InDex Pharmaceuticals.